capillary leak syndrome

Capillary leak syndrome (CLS) is characterized by the leakage of intravascular fluids into the extravascular space, leading to generalized edema and potential multiple organ failure. The condition can be triggered by various factors, including shock syndromes and ischemia-reperfusion injuries. Despite its severe manifestations, no specific genes have been identified, and the inheritance pattern remains unclear. The prevalence of CLS is extremely low, affecting fewer than 1 in 1,000,000 individuals, which contributes to the limited understanding of its clinical features.

The limited documentation surrounding capillary leak syndrome is primarily due to its extreme rarity, affecting fewer than 1 in 1,000,000 people. This rarity results in a lack of systematic clinical studies and comprehensive characterization of the condition. Additionally, the absence of identified genetic factors and defined inheritance patterns complicates the understanding of its clinical features.

Currently, there is an orphan drug in development, a fully human monoclonal antibody that activates the Tie2 receptor, which may offer potential therapeutic benefits for capillary leak syndrome. However, no clinical trials are available at this time. For updates on ongoing research and potential clinical trials, you can search ClinicalTrials.gov for relevant studies.